CN1248700C - Health-care food for preventing and treating hyperlipoidemia - Google Patents
Health-care food for preventing and treating hyperlipoidemia Download PDFInfo
- Publication number
- CN1248700C CN1248700C CN 03117705 CN03117705A CN1248700C CN 1248700 C CN1248700 C CN 1248700C CN 03117705 CN03117705 CN 03117705 CN 03117705 A CN03117705 A CN 03117705A CN 1248700 C CN1248700 C CN 1248700C
- Authority
- CN
- China
- Prior art keywords
- present
- capsule
- dosage
- health
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a health-care food for preventing and treating hyperlipoidemia. The present invention is characterized in that the present invention is made into an acceptable preparation, such as a tablet, a capsule and a medicinal granule, which is composed of raw material according to weight percentage as follows: 20% to 60% of red rice, 20% to 60% of cassia seeds, 10% to 40% of ganoderma and 10% to 30% of filling agent. The present invention uses fully plants which can be used as both foods and medicines as raw material; therefore, the present invention has the advantages of no toxicity, high safety and no side effect, has the functions of regulating blood fat and can obviously reduce TC and TG and increase HDL-c. Besides, the present invention has the advantages of convenient carrying, convenient taking and conspicuous curative effect, so the present invention is a necessary health-care product for the middle-aged and old persons.
Description
Technical field
The present invention relates to a kind of health product, especially a kind of health product-red Oletum Trogopterori preparation with prevention and treatment hyperlipidemia.
Background technology
Along with the sustainable development of China's economic and improving constantly of national life level, Chinese forward senescence society strides forward.A large amount of documents and materials show, cardiovascular disease be the influence in, the healthy first killer of old people, clinical data proves: hyperlipidemia is to bring out the most dangerous factor of coronary atherosclerotic heart disease, simultaneously, possible concurrent myocardial ischemia, angina pectoris, a series of cardiovascular disease such as acute cardiac muscle sudden death.The medicine of treatment hyperlipidemia is mainly the import chemicals at present.This series products, though the treatment hyperlipidemia tangible curative effect is arranged, stronger toxic and side effects is also arranged, in the influence, the old people healthy.
Summary of the invention
The object of the present invention is to provide a kind of is primary raw material with the food and medicament dual-purpose plant, has no side effect, and prevention and therapeutic effect significantly reduce the health product-red Oletum Trogopterori preparation of hyperlipidemia.
The present invention realizes by following technical proposal: it is made by following raw materials by weight percent:
Monas cuspurpureus Went 20～60%
Semen Cassiae 20～60%
Ganoderma 10～40%
Filler 10～30%.
In the starch of described filler employing medicine or food industry, mannitol, xylitol, the flavorant one or more are made any acceptable preparations such as tablet, capsule, electuary; Perhaps adopting solvent substrate is that in Polyethylene Glycol (PEG)-300～1000, propylene glycol, soybean oil, the Oleum Arachidis hypogaeae semen one or more are made acceptable soft capsule.
Described preparation all adopts process of the prior art and step to make.
Monas cuspurpureus Went in the described raw material claims redly bent ancient times again, is the Chinese crude drug of Dietotherapy double-purpose simply, it have help digestion invigorate blood circulation, the effect of the dry stomach of spleen invigorating, the Monas cuspurpureus Went of discovering in recent years has the effect of blood fat reducing, adjust blood pressure, blood sugar lowering simultaneously.The efficient HMG-COA reductase inhibitor Monaco1in k that separates from monascus, culture is the component for reducing blood fat that common people generally acknowledge.
Semen Cassiae has the effect of clearing away heat to improve acuity of vision, loosening bowel to relieve constipation.It contains Semen Cassiae protein and anthraquinone glycoside, can significantly reduce the index such as TC, TG, LDL-C of hyperlipidemia rats, is the important composition of preventing and treating hyperlipemia.Anthraquinone analog compound in the Semen Cassiae has the catharsis effect, can reduce intestinal to the absorption of cholesterol and increase it and drain, and come blood fat reducing by the absorption that reduces exogenous lipid.
Monacolin k in the Monas cuspurpureus Went can reduce the synthetic of cholesterol, and the anthraquinone glycoside in the Semen Cassiae can reduce the absorption of human body to cholesterol, and both share, and will play synergism.
Ganoderma is the Polyporaceae plant, and Ganoderma contains the acid of Ergota steroid, organic acid, glucosamine, polysaccharide, resin, mannitol etc., has effects such as the immunocompetence of raising, continuity aging.Consider that transferring the fat crowd mainly is the gerontal patient, general immunologic function is relatively poor, selects for use Ganoderma as adjuvant in this prescription, to improve the patient immune function, can tolerate the treatment and the preventive effect of blood lipid regulation better.
For showing effect of the present invention, the present invention is through animal experiment, and its result is as follows:
One, safety toxicology test
1, materials and methods
1.1, tried thing: the sub-capsule of red spirit, i.e. the present invention capsule.Adult amount is every day 2 times, and each 2, by adult 60Kg weighing machine, intake can be converted and is 22mg/kg.bw every day.
1.2, experimental animal: Kunming mouse, cleaning level (approval card number move word 19-052 number for Hubei Province doctor); The SD rat, cleaning level is from small rat (approval card number be: Shanghai is moving closes the card word No. 152), body weight 60-70 gram.
1.3, mice acute toxicity test (Horn ' s method): each 20 of male and female mices, body weight 18-21 gram is divided into four groups at random by body weight, each 5 of every group of male and female, dosage is followed successively by 1.00g/kg.bw, 2.15g/kg.bw, 4.64g/kg.bw, 10.00g/kg.bw.Each treated animal is after stopping eating 15 hours, and disposable per os is tried thing, observes continuously 7 days, writes down the toxic reaction situation and the dead number of elements of each treated animal, is tried the half lethal dose LD of thing to mice to determine this
50The results are shown in Table 1.
1.4, genetic toxicity test
1.4.1, Salmonella reversion test: adopt Salmonella typhimurium histidine defect type mutant TA
97, TA
98, TA
100, TA
102, establish 5000,1000,200,41,2 μ g/ wares totally 5 dosage groups, each dosage is established three parallel wares, and repeated trials is once.Positive control: MNNG 52 μ g, TA
100-S9,, TA
102-S9: fenaminosulf 50 μ g,, TA
97-S9,, TA
98-S9:2-aminofluorene 10 μ g, TA
97+ S9,, TA
98+ S9, TA
100+ S9:1,8-dihydroxyanthraquinone 50 μ g, TA
102+ S9.Establish feminine gender, solvent and blank group simultaneously.The results are shown in Table 2, table 3.
1.4.2, the PCEMNR micronucleus test: with 50 mices, each 25 of male and female, body weight 25-30 gram, be divided into five groups at random by body weight, male and female half and half, (being tried thing gives dosage and is followed successively by 1/8LD to be followed successively by negative control group (distilled water filling stomach), positive controls (cyclophosphamide 40mg/kg.bw), basic, normal, high three dosage groups
50, 1/4LD
50, 1/2LD
50).Each treated animal per os is tried thing or tester 2 times, irritates the stomach interval 24 hours, and irritates gastric capacity at every turn and be 0.2ml/10g.bw for twice, and in last irritate stomach after 6 hours the cervical vertebra dislocation put to death animal, get breastbone marrow smear, methanol is fixed, Giemsa dyeing, oily mirror microscopy.The results are shown in Table 4.
1.4.3, mouse sperm deformity test: 25 male mices of body weight 27-35 gram are divided into five groups at random, be negative control group (distilled water filling stomach), positive controls (cyclophosphamide 40mg/kg.bw), basic, normal, high three dosage groups, each treated animal filling stomach dosage and capacity are the same.Behind the continuous irrigation stomach 5 days, continue to feed 30 days, the cervical vertebra dislocation is put to death, and gets both sides epididymis smear, and methanol is fixed, Yihong dyeing, microscopy under the high power lens.The results are shown in Table 5.
1.5,30 days feeding trials of rat
1.5.1, dosage grouping: after 80 SD rat adaptabilities of male and female half and half are fed 5 days, be divided into four groups at random, be followed successively by matched group and basic, normal, high three dosage groups by body weight.Three dosage groups are tried thing by 25,50,100 times (being 0.55g/kg.bw, 1.10g/kg.bw, 2.20g/kg.bw) of human body recommended intake respectively.Tried thing and give to mix the feedstuff mode, the addition that is tried thing in 10%, three dosage treated animal feedstuff of rat daily paper appetite by its body weight is respectively 0.55%, 1.10%, 2.20%.
1.5.2, experimental technique: experimental session, each is organized the single cage of rat and raises, ad lib and drinking-water were fed 30 days continuously, calculated a food-intake, and claimed body weight weekly one time in per three days.Each treated animal is overnight during off-test stops eating, next day sacrificed by decapitation, taking internal organ is weighed and is compared group and the liver of high dose group, nephropathy are managed cut sections for microscopic examination, gets blood and makes analysis on hemogram and serum biochemistry index determining.The results are shown in Table 6, table 7, table 8, table 9, table 10, table 11.
Two, blood lipid regulation test
1, material and method
Sample: the preparation that the invention provides, adult every day 2 times, each 2, i.e. 0.22g/kg.bw.
Experimental animal: the SD rat, 50, male and female half and half, body weight are the 145-170 gram, the moving word of doctor 19-084 number.
Dosage is selected: high lipid food prescription %: normal feedstuff 88.7, Adeps Sus domestica 10, cholesterol 1, cholate 0.3.Experiment is established five groups, i.e. negative control group (normal diet), positive controls (high lipid food group), 10,20,30 multiple dose groups of human body recommended amounts, and feed high lipid food.
Dosage preparation: rat oral gavage amount 1ml/100g.bw.10 multiple dose groups: sampling 2.2g adds water to 100ml, 20 multiple dose groups: sampling 4.4g adds water to 100ml, 30 multiple dose groups: sampling 6.6g adds water to 100ml.
Experimental technique (the disorderly modelling prevention of lipid metabolism in rats type): the animal adaptability is raised 3d, and 12h weighs on an empty stomach, adopts tail blood, surveys serum TC and TG, according to blood lipid level, with reference to body weight, is divided into five groups at random, and 10 every group, male and female half and half.Negative control group (normal diet group), positive controls (high lipid food group), basic, normal, high test group, when giving high lipid food, give the thing that tried of various dose, animal ad lib and drinking-water schedule to last 28d, weigh weekly once, 28d adopts tail hematometry TC, TG, HDL-e in experiment.Latter stage is put to death animal in experiment, and the calm situation of anatomic observation rat body fat.Adopt the variance analysis method data statistics that experimentizes.The results are shown in Table 12, table 13, table 14, table 15, table 16.
Draw the present invention by said structure and have following advantage and effect:
1, because the plant of whole employing food and medicament dual-purposes is raw material, nontoxic.
2, every physiological and biochemical index there are no significant difference, the avirulence pathological changes, safety has no side effect.
3, have the blood lipid regulation effect, can obviously reduce TC, TG, HDL-c obviously raises.
4, have carry, taking convenience, evident in efficacy.
In sum, the present invention has the effect of significant prevention and treatment hyperlipidemia, be in, go into standing health product old age.
Embodiment 1
Prescription:
Monas cuspurpureus Went 60kg
Semen Cassiae 20kg
Ganoderma 10kg
Starch 10kg.
Preparation method: earlier Monas cuspurpureus Went, Semen Cassiae, Ganoderma are made powder, be processed into the capsule preparations of 0.33g/ grain or the tablet of 0.35g/ sheet by existing Technology.
Embodiment 2
By following prescription, become the soft capsule of 0.g/ grain with existing processes:
Monas cuspurpureus Went 20kg
Semen Cassiae 40kg
Ganoderma 10kg
PEG-400 15kg
Soybean oil 5kg
Propylene glycol 10kg.
Embodiment 3
By following prescription, become the electuary of 10g/ bag with existing processes:
Monas cuspurpureus Went 20kg
Semen Cassiae 20kg
Ganoderma 40kg
Starch 10kg
Mannitol 5kg
Flavorant 5kg.
The sub-blood fat regulating capsule of the red spirit of table 1 is to the acute toxicity of mice
| Group and dosage (g/kg.bw.) | Sex | Tried thing | Quantity (only) | Approach | Reaction of animals | Death toll (only) | Conclusion: LD 50 (g/kg.bw.) |
| 1.00 2.15 4.64 10.00 | Female | Red Oletum Trogopterori capsule | 5 5 5 5 | Per os is irritated stomach | Normal | 0 0 0 0 | ＞10.00 |
| 1.00 2.15 4.64 10.00 | Male | Red Oletum Trogopterori capsule | 5 5 5 5 | Per os is irritated stomach | Normal | 0 0 0 0 | ＞10.00 |
Table 2 Salmonella reversion test mixes method result (for the first time)
| Title | Dosage μ g/ ware | TA97 | TA98 | TA100 | TA102 | ||||
| -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | ||
| Red clever fat capsule blank solvent control is normally returned and is become clump count sodium azide fenaminosulf 2-aminofluorene 1,8-hydroxy-anthraquione | 5000 500 50 5 0.5 - 1.5 50 10 50 | 180±9.0 191±12.5 174±13.5 183±12.9 174±7.9 - 166±8.9 162±4.9 1477±87 | 184±15.4 175±17.1 183±11.7 176±11.6 184±16.5 - 164±11.0 164±6.5 2841±118 | 40.0±5.0 38.7±3.5 37.7±3.8 35.0±3.6 34.3±3.2 - 32.3±2.5 32.3±3.1 583±35 | 43.0±5.0 40.7±4.7 41.7±4.2 37.7±2.5 39.0±1.0 - 36.7±2.1 38.0±3.0 3270±144 | 183±9.7 177±8.0 171±14.6 180±12.1 180±8.3 - 174±6.2 180±10.0 1597±117 | 189±10.8 192±12.6 184±11.2 179±14.4 179±10.7 - 186±13.5 179±17.6 3253±87 | 311±12.5 295±18.3 298±11.1 294±15.5 283±12.7 288±11.5 294±7.8 1143±60 | 319±7.1 306±15.0 296±9.9 308±14.7 288±13.5 306±14.6 303±15.5 1357±97 |
Table 3 Salmonella reversion test mixes method result (for the second time)
| Title | Dosage μ g/ ware | TA97 | TA98 | TA100 | TA102 | ||||
| -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | ||
| Red clever fat capsule blank solvent control is normally returned and is become clump count MNNG fenaminosulf 2-aminofluorene 1,8-hydroxy-anthraquione | 5000 500 50 5 0.5 - 1.5 50 10 50 | 175±11.9 176±23.4 173±8.7 170±9.0 168±10.4 - 161±93 163±11.8 1453±75 | 179±10.8 181±9.5 176±7.6 173±5.7 176±12.1 - 167±9.1 164±6.6 2747±117 | 41.3±4.0 43.0±2.7 37.0±2.0 39.0±2.7 35.7±1.5 - 37.3±2.5 36.7±0.6 558±39 | 47.3±4.0 46.0±3.6 40.7±4.0 39.0±3.0 40.0±3.0 - 37.7±3.1 39.7±2.5 3680±147 | 186±7.1 182±11.5 179±13.5 164±11.0 167±10.7 - 180±12.8 171±9.1 1570±101 | 187±15.6 190±8.7 184±9.1 180±7.9 177±13.1 - 183±12.0 182±6.7 3190±110 | 302±13.0 287±11.9 287±12.2 286±6.7 291±11.5 - 285±14.0 303±4.7 1103±68 | 313±16.7 303±8.5 291±8.1 293±12.0 290±7.1 - 303±17.8 309±13.7 1323±93 |
The sub-blood fat regulating capsule of the red spirit of table 4 is to the influence of mouse bone marrow cells microkernel incidence
| Sex | Group and dosage (g/kg.bw.) | Number of animals (only) | Tried thing | Check cell number (individual) | Micronucleus number (individual) | Micronuclear rates (‰) | x 2 | P |
| Female | Negative control positive control 1.25 2.50 5.00 | 5 5 5 5 5 | ----cyclophosphamide capsule capsule capsule | 1000×5 1000×5 1000×5 1000×5 1000×5 | 8 128 10 6 11 | 1.6 25.6 2.0 1.2 2.2 | 5.495 ※ 130.588 △ | 0.139 ※ ＜0.001 △ |
| Male | Negative control positive control 1.25 2.50 5.00 | 5 5 5 5 5 | ----cyclophosphamide capsule capsule capsule | 1000×5 1000×5 1000×5 1000×5 1000×5 | 11 159 12 10 9 | 2.2 31.8 2.4 2.0 1.8 | 0.386 ※ 114.319 △ | 0.943 ※ ＜0.001^ |
The sub-blood fat regulating capsule of the red spirit of table 5 is to the influence of mouse sperm deformity incidence rate
| Group and dosage (g/kg.bw.) | Number of animals (only) | Tried thing | Examined sperm count (individual) | Sperm deformity number (individual) | Rate of teratosperm (%) | x 2 | P |
| Negative control positive control 1.25 2.50 5.00 | 5 5 5 5 5 | ----cyclophosphamide capsule capsule capsule | 1000×5 1000×5 1000×5 1000×5 1000×5 | 87 337 99 101 91 | 1.74 6.74 1.98 2.02 1.82 | 0.778 ※ 140.848^ | 0.855 ※ ＜0.001^ |
The sub-blood fat regulating capsule of the red spirit of table 6 is to the influence of rat body weight
| Sex | Group and dosage (g/Kg.bw.) | Number of animals (only) | Starting weight (g) | The 1st week (g) | The 2nd week (g) | The 3rd week (g) | End heavy (g) |
| Female | Contrast 0.55 1.10 2.20 | 10 10 10 10 | 81±7 81±6 81±6 82±6 | 116±8 113±6 115±8 113±6 | 133±9 131±7 133±9 127±9 | 148±10 148±7 147±10 143±10 | 163±13 159±11 157±11 154±12 |
| Male | Contrast 0.55 1.10 2.20 | 10 10 10 10 | 82±7 82±7 82±7 82±6 | 134±12 131±11 127±9 130±10 | 175±14 172±13 161±17 155±11 | 198±15 195±18 187±17 187±15 | 209±13 210±19 203±18 200±12 |
The sub-blood fat regulating capsule of the red spirit of table 7 is to the influence of rat total foodstuff utilization rate
| Sex | Group and dosage (g/Kg.bw.) | Number of animals (only). | Weight gain (g) | Food-intake (g) | Food utilization (%) | Statistic (F) | Probit (P) |
| Female | Contrast 0.55 1.10 2.20 | 10 10 10 10 | 81±13 78±9 76±11 73±10 | 430±30 425±33 395±44 416±33 | 18.9±2.6 18.4±2.2 19.3±2.5 17.4±2.0 | 1.19 | 0.3282 |
| Male | Contrast 0.55 1.10 2.20 | 10 10 10 10 | 127±11 128±19 121±16 118±10 | 547±54 531±53 537±51 486±47 | 23.4±2.9 24.0±2.5 22.6±1.8 24.4±2.5 | 1.07 | 0.3756 |
The sub-blood fat regulating capsule of the red spirit of table 8 is to the influence of Rats Organs and Tissues coefficient
| Sex | Dosage group (g/kg.bw.) | The heart (%) | Liver (%) | Kidney (%) | Spleen (%) | Testis (%) |
| Female | Contrast 0.55 1.10 2.20 | 0.40±0.05 0.38±0.04 0.37±0.04 0.38±0.07 | 3.12±0.46 3.15±0.37 3.25±0.18 3.44±0.49 | 0.72±0.08 0.68±0.07 0.68±0.06 0.70±0.09 | 0.31±0.06 0.30±0.05 0.34±0.03 0.31±0.07 | |
| Male | Contrast 0.55 1.10 2.20 | 0.37±0.05 0.36±0.03 0.36±0.03 0.38±0.05 | 3.22±0.52 3.11±0.34 3.12±0.28 3.15±0.39 | 0.70±0.09 0.71±0.07 0.73±0.05 0.69±0.07 | 0.30±0.06 0.31±0.07 0.34±0.08 0.34±0.07 | 1.12±0.06 1.18±0.11 1.18±0.10 1.17±0.07 |
The sub-blood fat regulating capsule of the red spirit of table 9 is to the influence of rat blood biochemical indicator
| Sex | Group and dosage (g/Kg.bw.) | Number of animals (only) | GPT (U/L) | GOT (U/L) | BUN (mmol/L) | Glu (mmol/L) | Cre (μmol/L) |
| Female | Contrast 0.55 1.10 2.20 | 10 10 10 10 | 57.7±8.7 54.1±9.8 50.8±9.8 60.3±11.7 | 149±21 144±22 158±16 153±17 | 5.72±0.49 5.43±0.95 5.80±0.73 6.21±0.82 | 5.79±0.48 5.73±0.49 6.16±0.63 5.75±0.73 | 102.5±3.0 93.0±13.6 92.8±15.1 96.5±11.4 |
| Male | Contrast 0.55 1.10 2.20 | 10 10 10 10 | 54.0±7.9 49.9±8.8 62.9±10.4 50.9±7.8 | 138±22 153±13 147±25 149±21 | 5.99±0.65 5.83±0.80 5.98±0.86 5.58±0.50 | 5.80±0.65 5.26±0.48 5.52±0.49 5.65±0.33 | 96.4±13.9 91.6±8.4 102.5±15.3 98.8±11.1 |
The sub-blood fat regulating capsule of the red spirit of table 10 is to the influence of rat blood biochemical indicator
| Sex | Group and dosage (g/Kg.bw.) | Number of animals (only) | TC (mmol/L) | TG (mmol/L) | TP (g/L) | Alb (g/L) |
| Female | Contrast 0.55 1.10 2.20 | 10 10 10 10 | 2.04±0.23 1.86±0.24 1.85±0.23 1.77±0.24 * | 0.85±0.10 0.73±0.15 0.78±0.19 0.66±0.15 * | 66.2±3.9 68.0±1.4 67.9±1.9 67.5±2.3 | 41.5±5.1 42.8±2.9 41.2±2.0 41.8±2.7 |
| Male | Contrast 0.55 1.10 2.20 | 10 10 10 10 | 2.08±0.30 1.96±0.24 2.00±0.26 1.84±0.21 | 0.81±0.14 0.76±0.15 0.70±0.09 0.66±0.10 | 65.5±1.6 66.9±2.3 66.7±3.3 67.3±2.6 | 39.5±3.6 41.4±3.8 41.1±4.4 42.6±3.3 |
The sub-blood fat regulating capsule of the red spirit of table 11 is to the influence of rat blood index
| Sex | Dosage (g/kg.bw.) | RBC (×10 12/L) | Hb (g/L) | WBC (×10 9/L) | WBC classify (%) | |||
| Lymph | Neutral grain | Monokaryon | Other | |||||
| Female | Contrast 0.55 1.10 2.20 | 7.64±1.12 7.84±1.17 7.92±0.38 8.32±0.53 | 148±13 150±15 156±9 150±16 | 8.16±1.01 8.77±1.76 8.06±1.18 8.90±1.16 | 77.2±2.9 77.7±3.4 77.1±3.8 76.9±2.3 | 18.0±3.0 19.4±2.6 20.3±4.4 20.0±2.2 | 1.6±1.0 1.6±1.1 1.5±0.8 1.9±0.7 | Each group is all between 0～1 |
| Contrast 0.55 1.10 2.20 | 8.19±0.42 8.05±0.70 7.93±0.53 8.02±0.68 | 156±9 146±12 146±13 151±18 | 8.68±1.07 7.87±1.00 8.39±1.40 7.79±1.43 | 76.3±3.1 78.0±3.1 77.1±3.8 74.0±3.7 | 20.6±2.5 19.4±2.8 20.3±4.4 18.5±3.2 | 1.9±1.1 1.7±1.2 1.3±1.1 1.5±1.0 | ||
The sub-blood fat regulating capsule of the red spirit of table 12 to the influence of rat body weight (X ± SD, g)
| Dosage g/Kg.bw | Number of animals (only) | Body weight | Weightening finish | |
| Before the test | After the test | |||
| Negative control positive control 0.22 0.44 0.66 | 10 10 10 10 10 | 155±7 155±7 155±8 153±4 156±6 | 265±48 258±30 251±36 249±24 253±33 | 111±49 103±30 97±35 96±23 97±33 |
The sub-blood fat regulating capsule of the red spirit of table 13 to the influence of serum TC before and after the rat test (X ± SD, mmol/L)
| Dosage (g/Kg.bw) | Number of animals (only) | Before the experiment (0d) | 28d |
| Negative control positive control 0.22 0.44 0.66 | 10 10 10 10 10 | 1.77±0.26 1.77±0.22 1.79±0.39 1.78±0.17 1.77±0.28 | 1.81±0.23 5.27±0.65 4.46±0.52 4.19±0.68 3.97±0.73 |
The sub-blood fat regulating capsule of the red spirit of table 14 to the influence of serum TG before and after the rat experiment (X ± SD, mmol/L)
| Dosage (g/Kg.bw) | Number of animals (only) | Before the experiment (0d) | 28d |
| Negative control positive control 0.22 0.44 0.66 | 10 10 10 10 10 | 0.82±0.16 0.85±0.15 0.83±0.19 0.91±0.20 0.81±0.16 | 0.79±0.17 1.59±0.24 1.43±0.30 1.45±0.31 1.28±0.21 |
The sub-blood fat regulating capsule of the red spirit of table 15 to the influence of serum hdl-c before and after the rat experiment (X ± SD, mmol/L)
| Dosage (g/Kg.bw) | Number of animals (only) | Before the experiment (0d) | 28d |
| Negative control positive control 0.22 0.44 0.66 | 10 10 10 10 10 | 0.82±0.10 0.85±0.06 0.87±0.27 0.86±0.20 0.83±0.12 | 0.82±0.10 0.58±0.07 0.90±0.15 0.83±0.14 0.81±0.14 |
The sub-blood fat regulating capsule of the red spirit of table 16 is to the influence of rat fat level
| Dosage (g/Kg.bw) | Number of animals (only) | TC (％) | TG (％) | HDL-c (g/dl) |
| 0.22 0.44 0.66 | 10 10 10 | 15.4 20.5 18.4 | 10.1 8.8 19.5 | 12.4mg/dl 9.7mg/dl 8.90mg/dl |
| Criterion: | Descend＞10%, | Descend＞15%, | Rising 4mg/d |
Claims (3)
1, the health product of a kind of prevention and treatment hyperlipidemia is characterized in that it is made by following raw materials by weight percent:
Monas cuspurpureus Went 20～60%
Semen Cassiae 20～60%
Ganoderma 10～40%
Filler 10～30%.
2, health product according to claim 1 is characterized in that described filler adopts in the starch, mannitol, xylitol, flavorant of medicine or food industry one or more to make a kind of acceptable preparation in tablet, capsule, the electuary.
3, health product according to claim 1 is characterized in that adopting in Liquid Macrogol～1000, propylene glycol, soybean oil, the Oleum Arachidis hypogaeae semen one or more to make soft capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03117705 CN1248700C (en) | 2003-04-14 | 2003-04-14 | Health-care food for preventing and treating hyperlipoidemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03117705 CN1248700C (en) | 2003-04-14 | 2003-04-14 | Health-care food for preventing and treating hyperlipoidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1537632A CN1537632A (en) | 2004-10-20 |
| CN1248700C true CN1248700C (en) | 2006-04-05 |
Family
ID=34320634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03117705 Expired - Fee Related CN1248700C (en) | 2003-04-14 | 2003-04-14 | Health-care food for preventing and treating hyperlipoidemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1248700C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325089C (en) * | 2005-02-06 | 2007-07-11 | 杭州鑫富药业有限公司 | Chinese patent medicine on health food composition and its use |
| CN1919214B (en) * | 2005-08-24 | 2010-05-05 | 成都地奥九泓制药厂 | Monascus soft capsule and its preparation method |
| CN100364553C (en) * | 2005-12-12 | 2008-01-30 | 西安利君制药有限责任公司 | Natural medicinal composition for preparing diabete drug |
| CN105055461A (en) * | 2015-07-23 | 2015-11-18 | 广西仙草堂制药有限责任公司 | Lipid-lowering Ganoderma health product and its preparation method |
-
2003
- 2003-04-14 CN CN 03117705 patent/CN1248700C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1537632A (en) | 2004-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1267013C (en) | Composition for improving glucose and insulin metabolism in companion animals | |
| CN1723953A (en) | Herb medicine | |
| CN1669478A (en) | Preparation method of vinegar-egg powder, compound containing vinegar-egg powder and application thereof | |
| CN1921771A (en) | Composition for preventing a cold | |
| CN1255376A (en) | Method of enhancing crude drugs anti-tumour activity | |
| CN1384750A (en) | Plant extract mixtures and their uses | |
| CN1911102A (en) | Compounding agent for sobering and health-care, and its prodn, method | |
| CN101049323A (en) | Health protection medicine in use for treating chronic degenerative diseases, and producing method | |
| CN1224329C (en) | Feed additive made of herbal medicine compound concentrate, and its prepn. method | |
| CN1248700C (en) | Health-care food for preventing and treating hyperlipoidemia | |
| CN1245971C (en) | Tea-polyphenol soft capsule and its preparation process | |
| CN101040645A (en) | Lotus tea having health-care and weight-losing effect | |
| CN1433315A (en) | Radioprotecting agent | |
| CN1901927A (en) | Alpha-glucosidase activity inhibitor | |
| CN1698676A (en) | Litchi peel extract and preparation method and application thereof | |
| US20220305069A1 (en) | A preparation method of antrodia cinnamomea water-insoluble dietary fiber | |
| CN101361800A (en) | Traditional Chinese medicine for reducing blood fat and enhancing effect and reducing toxin of statins medicine and preparation method thereof | |
| CN1843205A (en) | Preparation process of health food for preventing and treating cardiovascular and cerebrovascular disease | |
| CN1296059C (en) | Mackefulan immune liquid | |
| CN1184901C (en) | Health-care Zaozhishen food | |
| CN1174037A (en) | Monascus preparation for hyperlipemia and relevant cardiac and cerebral diseases | |
| CN101084933A (en) | Medicinal composition for strengthening immunity and its preparing process | |
| JP2004121070A (en) | Health food | |
| CN1173908C (en) | Method for converting derivative of internal inositol of buckwheat seed into its monomer and its seed | |
| CN1121237C (en) | Health-care products for regulating immunological function and delaying senility |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060405 Termination date: 20120414 |